Anti-platelet agents have left an indelible impression in the management of a wide range of pathologies. From the earliest
therapeutic agents such as aspirin, to the cutting edge agents still undergoing development, they have the capability to powerfully manipulate
platelet biology, a central player in thrombosis. The use of these agents is still subject to a number of important limitations that
two newer agents, prasugrel and ticagrelor, aim to address. Both have recently received licensing for use in acute coronary syndromes
and promise to improve outcomes for patients. Here, we examine the rationale for the development and clinical integration of antiplatelet
agents focusing upon prasugrel and ticagrelor.
Keywords: Platelet inhibitors, P2Y12 receptor, acute coronary syndrome, clopidogrel, prasugrel, ticagrelor
Rights & PermissionsPrintExport